STOCK TITAN

Evotec Ag - EVO STOCK NEWS

Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.

About Evotec AG

Evotec AG (symbol: EVO) is a globally recognized life sciences company that excels in drug discovery and development, delivering comprehensive solutions for pharmaceutical, biotechnology, and academic partners. With a highly synergistic multimodality platform, Evotec integrates advanced technologies, robust data analytics, and innovative scientific approaches to facilitate the discovery, development, and production of both first-in-class and best-in-class therapeutics.

Comprehensive Business Model

Evotec operates through a unique business model characterized by:

  • Shared R&D Services: Providing tailored drug discovery and manufacturing services on a fee-for-service basis, this segment forms the core of their operations and fuels a significant portion of their revenues.
  • Collaborative Partnerships: Engaging in co-creation partnerships with Top 20 Pharma companies, over 800 biotechnology firms, academic institutions, and nonprofit organizations, Evotec extends its reach across a broad spectrum of therapeutic areas.
  • CDMO and Biologics: Through its Just-Evotec Biologics segment, the company offers specialized contract development and manufacturing operations, particularly in the biologics arena, ensuring high-quality production capabilities.

This diversified model emphasizes strategic alliances, allowing the company to efficiently bridge academic research and commercial development, thereby accelerating the path from bench to bedside.

Innovative Therapeutic Focus

Evotec is renowned for its dedication to addressing unmet medical needs across a variety of therapeutic areas. Key focus areas include:

  • Central nervous system disorders
  • Oncology and metabolic diseases
  • Inflammation and infectious diseases
  • Women's health
  • Emerging areas such as stem cell-based therapies and precision medicine

Each area is supported by a robust research and development structure, where Evotec leverages proprietary assets alongside collaborative research initiatives to push the boundaries of modern medicine.

Global Operational Footprint

Headquartered in Hamburg, Germany, Evotec maintains a strong global presence with production and R&D sites strategically located across Europe and the United States. This international network not only enhances efficiency in operations but also ensures the company can tap into diverse scientific expertise and market dynamics.

Commitment to Excellence and Expertise

Evotec's commitment to quality and innovation is mirrored by its extensive portfolio of co-owned and proprietary research projects, spanning the full spectrum of drug development — from early discovery through to clinical development. By fostering an environment of collaborative excellence and incorporating state-of-the-art technologies, the company continuously reinforces its standing in the competitive pharmaceutical services sector.

Position within the Competitive Landscape

In an industry where precision and innovation are paramount, Evotec distinguishes itself through its integrated approach and proven track record of successful partnerships. The company’s ability to adapt its service offerings to meet evolving client needs and cutting-edge scientific challenges positions it as a formidable partner for stakeholders across the biopharmaceutical spectrum. Its operational excellence and commitment to groundbreaking research underscore a strategic focus on delivering high-quality therapeutic solutions without speculative projections or promotional language.

Conclusion

Evotec AG exemplifies a well-structured, innovative, and collaborative approach to advancing pharmaceutical research. Its robust service offerings, global presence, and diversified therapeutic portfolio provide invaluable insights for investors seeking to understand the dynamics of the life sciences sector. By maintaining a clear focus on strategic R&D initiatives and forming key alliances, Evotec continues to drive progress in the field of drug discovery and development.

Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has expanded its relationship with Advanced BioScience Laboratories, Inc. to develop a third broadly neutralising antibody (bNAb) against HIV. The collaboration aims to provide large-scale cGMP manufacturing campaigns for the bNAb and a previously developed bNAb for a Phase I clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News
Rhea-AI Summary
Evotec SE is holding a conference call to provide a business update and a statement on its commitment to corporate governance standards. The call will feature the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich, and CEO Dr. Mario Polywka, discussing the company's strategy, recent market developments, and unchanged views on Guidance 2023 and the 2025 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
none
-
Rhea-AI Summary
Evotec SE (EVT) collaborates with the Crohn's & Colitis Foundation's IBD Therapeutics Incubator to advance drug discovery for inflammatory bowel disease (IBD). The collaboration focuses on developing innovative drug targets addressing fibrosis and impaired intestinal barrier function. Evotec's end-to-end integrated R&D platform will be utilized to translate groundbreaking basic research into medical innovations for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
Rhea-AI Summary
Evotec SE (EVT) announced a scientific achievement in its strategic partnership with Bristol Myers Squibb, resulting in a US$ 25 million payment to further research the joint neuroscience pipeline. The collaboration aims to develop disease-modifying treatments for neurodegenerative diseases, with a successful Phase I study leading to a Phase II study for BMS-986419 scheduled to commence in 2024. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, expressed confidence in delivering new therapeutic options for patients affected by neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
partnership
-
Rhea-AI Summary
Evotec SE (EVT) and Owkin Announce A.I.-Powered Collaboration in Oncology, Immunology, and Inflammation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
partnership
-
News
Rhea-AI Summary
Evotec SE (EVT) announces CEO Dr. Werner Lanthaler's resignation for personal reasons. Dr. Mario Polywka to serve as interim CEO. The company confirms its 2023 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.81%
Tags
none
Rhea-AI Summary
Evotec SE (EVT) has received a US$ 2.5 million grant from the Bill & Melinda Gates Foundation for its teratogenicity platform and joins the foundation's Global Health Discovery Collaboratory. The grant provides GHDC members access to Evotec's high-throughput teratogenicity platform at no extra cost, enabling cost-effective de-risking of drug candidates early in the discovery process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
Evotec SE (EVT) partners with Charité Universitätsmedizin Berlin to create a molecular patient database for ANCA-associated vasculitis, a group of rare autoimmune diseases. The partnership aims to improve disease understanding and treatment through the analysis of patient material using Evotec's PanOmics platform. Charité will collect biosamples, and Evotec will leverage its M.L.-powered platform to translate research into precision therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.29%
Tags
partnership
-
Rhea-AI Summary
Evotec SE (EVT) announced that its license partner, Zhejiang Jingxin Pharmaceutical Co., Ltd, has received approval from the Chinese National Medical Products Administration for the novel insomnia treatment EVT201, also known as Dimdazenil in China. This treatment is a partial positive allosteric modulator of the GABAA receptor with high affinity and moderate efficacy. Evotec will receive double-digit royalties of net sales as well as milestones based on commercial success and further sub-licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
Rhea-AI Summary
Evotec SE (EVT) Presents Precision Medicine Capabilities at Capital Markets Day, Highlighting PanOmics, iPSC, and A.I./M.L. Platforms. The company confirms Action Plan 2025 goals and updates progress, showcasing investments of ~€450m into PanOmics and iPSCs, resulting in cumulated revenues of >€1bn and creating a milestone pool of >€15bn. The event emphasizes the introduction of a differentiated offering to shape untapped markets, fostering double-digit growth, and discusses the next big developments in the co-owned pipeline with insights to novel first-in-class targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none

FAQ

What is the current stock price of Evotec (EVO)?

The current stock price of Evotec (EVO) is $2.97 as of April 7, 2025.

What is the market cap of Evotec (EVO)?

The market cap of Evotec (EVO) is approximately 1.1B.

What is Evotec AG's core business model?

Evotec AG operates through a dual approach, offering fee-for-service drug discovery and manufacturing services alongside collaborative partnerships in R&D and biologics CDMO operations.

In which therapeutic areas does Evotec specialize?

The company is active in multiple areas including central nervous system disorders, oncology, metabolic diseases, inflammation, infectious diseases, and emerging fields such as stem cell-based therapies.

How does Evotec generate revenue?

Revenue is largely generated through its shared R&D services on a fee-for-service basis and through contract development and manufacturing, particularly in the biologics sector.

What makes Evotec a significant player in the pharmaceutical services industry?

Evotec’s strength lies in its integrated platform, robust global presence, and strong network of strategic partnerships with major pharmaceutical companies, biotech firms, and academic institutions.

Where is Evotec headquartered and what is its global footprint?

Headquartered in Hamburg, Germany, Evotec has multiple production and research sites across Europe and the United States, ensuring comprehensive global operations.

How does Evotec enhance its R&D capabilities?

The company leverages a combination of internally developed assets and external collaborations to drive innovation, ensuring a robust pipeline from early discovery to clinical development.

What role do strategic partnerships play in Evotec's operations?

Strategic partnerships allow Evotec to co-create innovative therapies and expand its service offerings, enabling efficient translation of scientific research into therapeutic solutions.
Evotec Ag

OTC:EVO

EVO Rankings

EVO Stock Data

1.09B
354.61M
2.52%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg